In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Surgical Cures in Hormone-Secreting Cavernous Sinus Pituitary Macroadenomas: First Reported Cases

    Final Number:

    Ali F. Krisht MD; Svetlana Pravdenkova MD, PhD; Sharon Partington RN; Agustin Dorantes-Argandar MD

    Study Design:

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2011 Annual Meeting

    Introduction: Hormone-secreting cavernous sinus (CS) pituitary macroadenomas are treated with partial resection followed by radiation and/or medication. This results in treatment failures and/or radiation related complications. We present, for the first time, microsurgical cures in hormone-secreting CS pituitary macroadenomas using a predominantly epidural pretemporal transcavernous approach to the sellar and parasellar region.

    Methods: 42 microsurgically treated CS pituitary macroadenomas were prospectively followed and retrospectively analyzed. The pretemporal, predominantly epidural, transcavernous approach was utilized. Patients' hormonal, clinical, endocrine, immuno-histopathological, and radiological outcomes were studied. Our microsurgical approach differs from previous reported approaches by accessing all the different CS anatomical compartments. In cases where cures were not achieved, this approach minimized the post-surgical adjuvant treatment to very small radiosurgical volume. Average follow-up = 47.08 +/-44.54 with median of 36 months).

    Results: Of 42 (F/M=19/23) patients with CS pituitary macroadenomas treated with microsurgical resection, 25 % were recurrent tumors. 23 (55 %) were hormonally active. 37 tumors were histopathologically benign and 5 were either atypical or malignant. Of the 23 hormonally active tumors (Growth hormone=10, Prolactin=5, Gonadotropic=4, ACTH=2, TSH=2). Hormonal cures were achieved in 43 % of patients (Growth Hormone=5, ATCH=1, Prolactin=3, Gonadotropic=1). The cures were more frequent in the non-recurrent, non-malignant, more recently operated cases. There was no surgical mortality. Cranial neuropathies were transient in all patients except for the malignant cases.

    Conclusions: Mastering the microanatomy of the CS and understanding the pathological anatomic changes can help achieve safe and radical resection of cavernous sinus pituitary macroadenomas. This is the first time microsurgical cures are reported in hormonally-active CS pituitary macroadenomas. We consider this a surgical breakthrough that will positively impact the future treatment of a large population of patients who suffer from these debilitating diseases.

    Patient Care: Adding a new treatment option for treating hormonally active cavernous sinus pituitary adenomas.

    Learning Objectives: To understand new surgical approaches for treatment of cavernous sinus pituitary adenomas. To understand the management of invasive cavernous sinus pituitary adenomas.


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy